This study looks at a medicine called efruxifermin (EFX) for people with a liver condition called Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH) with some liver damage, known as fibrosis. NASH/MASH is a liver disease caused by fat buildup in the liver, not due to alcohol. This study checks if EFX can help improve liver health. Participants will be randomly assigned to receive either the medicine or a placebo (a "dummy" treatment). The study is "double-blind," which means neither the participants nor the researchers know who gets the medicine or the placebo.

• Participants must be 18 to 80 years old and have certain health conditions, like obesity or diabetes.
• The study will last for a certain period, and participants will need to visit the study center multiple times.
• There may be risks or side effects, so it's important to talk to a doctor.